Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
Benjamin Besse(Institut Gustave Roussy), Claude El Kouri(Université de Montpellier), Federico Cappuzzo(Ospedale di Livorno), Anne Madroszyk(Institut Paoli-Calmettes), Patrick Masson(Institut de Physique et Chimie des Matériaux de Strasbourg), C. Chouaïd(Université de Montpellier), Michele Maio(University of Siena), Domenico Galetta(Istituto Tumori Bari), Giuseppe Giaccone(Cornell University), Céline Mascaux(Hôpitaux Universitaires de Strasbourg), Benoît Roch(Université de Montpellier), Manuel Cobo(Instituto de Investigación Biomédica de Málaga), D. Debieuvre(Groupe Hospitalier de la Région de Mulhouse et Sud Alsace), Fabrice Denis(Centre Jean Bernard), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Alexis B. Cortot(Centre National de la Recherche Scientifique), Santiago Viteri(Instituto Oncológico Dr. Rosell), Gianpiero Romano(Ospedale Vito Fazzi), B. Vasseur(Université de Montpellier), Rafał Dziadziuszko(Gdańsk Medical University), Julien Mazières(Université Toulouse III - Paul Sabatier), Jordi Remón(Vall d'Hebron Hospital Universitari), Boris Duchemann(Université Paris-Saclay), Alona Zer(Rambam Health Care Campus), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), B. Delclaux(Université de Montpellier), D Costantini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Clément Bonnet(Université de Montpellier), O. Molinier(Centre Hospitalier de Lens), Werner Hilgers(Institut Sainte Catherine), Editta Baldini, Milada Zemanová, Enriqueta Felip(Institut Català d'Ornitologia), Wolfgang Schuette(Martha-Maria Hospital), M. Razaq(Oklahoma State University Oklahoma City), François‐Régis Ferrand, G. Robinet(Centre Hospitalier Régional Universitaire de Brest), M. Ginoux(Centre Hospitalier de Lens), Rosario García Campelo(Universidade da Coruña), Éric Pichon(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Jacques Cadranel(Sorbonne Université)
Cited by 69
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k